Evgen Pharma PLC (EVG)

London
Currency in GBP
Disclaimer
2.09
-0.01
(-0.52%)
Real-time Data
Day's Range
2.09
2.09
52 wk Range
1.93
7.80
Volume
58,640
Bid/Ask
2.00 / 2.20
Prev. Close
2.1
Open
2.1
Day's Range
2.09-2.09
52 wk Range
1.93-7.8
Volume
58,640
Average Volume (3m)
465,577
1-Year Change
-37.31%
Shares Outstanding
274,888,117
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about EVG?
Vote to see community's results!
or

Evgen Pharma PLC Company Profile

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company’s lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Income Statement